Abstract: A genetically modified mouse is provided, wherein the mouse expresses an immunoglobulin light chain repertoire characterized by a limited number of light chain variable domains. Mice are provided that express just one or a few immunoglobulin light chain variable domains from a limited repertoire in their germline. Methods for making bispecific antibodies having universal light chains using mice as described herein, including human light chain variable regions, are provided. Methods for making human variable regions suitable for use in multispecific binding proteins, e.g., bispecific antibodies, and host cells are provided. Bispecific antibodies capable of binding first and second antigens are provided, wherein the first and second antigens are separate epitopes of a single protein or separate epitopes on two different proteins are provided.

Abstract: The method and system of high-resistance, multiple-conductor flat cables which contain integral tunable resistance sections suitable for fine tuning the resistance of a conductor to match the resistance of the conductors to one another within a specified target value. The method involves the design and creation of the high-resistance, multiple-conductor flat cables and the tuning of the resistance of the conductor.

Abstract: The method and system of high-resistance, multiple-conductor flat cables which contain integral tunable resistance sections suitable for fine tuning the resistance of a conductor to match the resistance of the conductors to one another within a specified target value. The method involves the design and creation of the high-resistance, multiple-conductor flat cables and the tuning of the resistance of the conductor.

Abstract: New mutations have been found in the BRCA1 gene. The mutations are located at nucleotide numbers 421-2, 815, 903, 926, 1506, 2034, 2428, 3888, 3904, 4164, 4643, 5053, 5150, 5210, or 5396+40 of the gene sequence of BRCA1. A process for identifying a sequence variation in a BRCA1 polynucleotide sequence is disclosed. The identification process includes allele specific sequence-based assays of known sequence variations. The methods can be used for efficient, and accurate detection of a mutation in a test BRCA1 gene sample.